使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings and welcome to the Align Technology Inc., Q2 2016 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. (Operator Instructions).
各位好,歡迎參加 Align Technology Inc. 2016 年第二季(Q2)財報電話會議。此刻所有與會者皆處於僅收聽模式。正式簡報結束後將進行問答環節。(接線員指示)
I would now like to turn the conference over to your host, Shirley Stacy, VP of Corporate and Investor Communications, please go ahead.
現在我想把會議交給主持人——企業與投資人溝通副總裁 Shirley Stacy,請開始。
Shirley Stacy - VP, Corporate Communications and IR
Shirley Stacy - VP, Corporate Communications and IR
Good afternoon and thank you for joining us, I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO and David White, CFO.
各位下午好,感謝各位加入。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 David White。
We issued second quarter 2016 financial results today via Marketwired, which is available on our website at Investor.Aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months.
我們已於今日透過 Marketwired 發布 2016 年第二季財務結果,並可在我們網站 Investor.Aligntech.com 取得。今天的電話會議將以音訊網路直播,並會在我們網站上保存約 12 個月。
A telephone replay will be available today by approximately 5:30 PM Eastern Time through 5:30 PM Eastern Time on August 11. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13640324 followed by pound. International callers should dial 201-612-7415 with the same conference number.
電話重播將於今日約美東時間下午 5:30 起提供,並持續至 8 月 11 日美東時間下午 5:30。欲收聽電話重播,美國境內來電者請撥 877-660-6853,輸入會議編號 13640324 後按井字鍵。國際來電者請撥 201-612-7415,並輸入相同會議編號。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the third quarter of 2016. These forward-looking statements are only predictions and involve risks and uncertainties such that set forth in more detail in our recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly and Align expresses no obligation to update any forward-looking statements.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2016 年第三季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們近期向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 不承擔更新任何前瞻性陳述之義務。
We have posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliations and our second quarter conference call slides on our webcast under Quarterly Results. Please refer to these files for more detailed information.
我們已在網路直播的「季度結果」專區張貼一組 GAAP 與非 GAAP 歷史財務報表(含相對應調節表),以及第二季電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。
With that, I'll turn the call over to Align Technology President and CEO, Joe Hogan. Joe?
接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Thanks Shirley, good afternoon and thanks for joining us. On our call today I'll provide some financial highlights and then briefly discuss the performance of our two operating segments; Invisalign Clear Aligners and Scanners. Dave will provide more detail on our financials and discuss our outlook for the third quarter. Following that I'll come back and summarize a few key points and open up the call to questions.
謝謝 Shirley,各位下午好,感謝各位加入。今天的電話會議我會先提供一些財務重點,接著簡要說明我們兩個營運部門的表現:Invisalign 隱形矯正器與掃描器。Dave 會更詳細說明財務狀況並討論第三季展望。之後我會再回來總結幾個重點並開放提問。
Q2 was driven by a better than expected revenue due to continued strong year-over-year Invisalign volume across our customer base and record utilization with international case volume up 38.3% and North America up 15.3%. we also had continued strong demand for our iTero element with record shipments this quarter resulting in revenue growth of almost 200% year-over-year.
第二季的表現主要受惠於營收優於預期,原因是我們客戶群的 Invisalign 量能持續強勁、年增表現亮眼,且使用率創新高:國際病例量成長 38.3%,北美成長 15.3%。此外,iTero element 需求亦持續強勁,本季出貨量創新高,使營收年增近 200%。
Q2 North America Clear Aligner volume was up 4% sequentially and 50% year-on-year. On a sequential basis, Q2 growth was driven by both orthodontists and GP customers, utilization among our orthodontist customers continued to increase and we reached record levels in both ortho and GP channels for a total of 10.7 cases per doctor this quarter.
第二季北美隱形矯正器量能季增 4%、年增 50%。以季比來看,第二季成長同時來自矯正專科醫師與一般牙醫(GP)客戶;矯正專科客戶的使用率持續提升,本季在矯正專科與 GP 兩個通路皆達到創紀錄水準,合計每位醫師平均 10.7 例。
On a year-over-year basis our Q2 volume growth rate continues to outpace our three-year average driven by increased ortho utilization as well as expansion of our GP customer base.
以年比來看,我們第二季的量能成長率持續高於三年平均,主要由矯正專科使用率提升,以及 GP 客戶基礎擴張所帶動。
Q2 Invisalign volume for international doctors is up 17% sequentially and 38% year-over-year. Continued strength reflects record international utilization driven by EMEA as well as continued expansion of our customer base in APAC. We're also seeing increased use of Invisalign G5 for deep bite in EMEA as well as our Invisalign G6 for extraction cases in APAC both showing momentum in the quarter and nearly equaling the overall growth rate for each respective region.
第二季國際醫師的 Invisalign 量能季增 17%、年增 38%。持續的強勁表現反映國際使用率創新高,主要由 EMEA 帶動,同時 APAC 客戶基礎也持續擴張。我們也看到 EMEA 地區對用於深咬(deep bite)的 Invisalign G5 使用增加,以及 APAC 地區對用於拔牙病例的 Invisalign G6 使用增加;兩者在本季皆展現動能,且幾乎與各自區域的整體成長率相當。
In EMEA, Q2 volume was up 37% year-over-year led by Spain, France and the Netherlands. Smaller country markets such as the Nordic and Eastern Europe also had strong year-over-year growth although off a smaller base. Execution of our [High Touch] TFM program is expanding our focused approach across all of our markets in Europe and starting to deliver stronger growth. Our low stage Lite and i7 product continued to contribute incremental growth. In Asia-Pacific record shipments in Q2 resulted in 42% growth year-over-over. Growth is very strong again in China, Japan, South Asia and Taiwan.
在 EMEA,第二季量能年增 37%,主要由西班牙、法國與荷蘭帶動。北歐與東歐等較小國家市場亦有強勁年增,雖然基期較小。我們的 [High Touch] TFM 計畫執行,正把聚焦式作法擴展至歐洲各市場,並開始帶來更強的成長。我們的低階段 Lite 與 i7 產品也持續貢獻增量成長。在亞太地區,第二季出貨量創新高,帶動年增 42%。中國、日本、南亞與台灣的成長再次非常強勁。
Q2 was a busy quarter for customer events, it's more than 700 doctors and clinical staff attending our second annual Invisalign APAC summit in Macao. In addition, we had more than 500 orthodontists attend our country-focused forum in China. We've continued to ramp up doctors training in APAC with particular focus on developing doctors in newer markets such as India, Korea and Taiwan. In fact, more than a hundred doctors in Taiwan were trained in June alone. The important team segment, the total number of Invisalign cases worldwide in Q2 increased 20% year-over-year, reflected continued adoption of Invisalign treatment for teenagers 11 to 19 years.
第二季客戶活動相當密集,超過 700 位醫師與臨床人員參加我們在澳門舉辦的第二屆 Invisalign APAC 高峰會。此外,超過 500 位矯正專科醫師參加我們在中國舉辦、以國家為主題的論壇。我們持續加速 APAC 醫師訓練,特別聚焦於印度、韓國與台灣等較新市場的醫師培育。事實上,僅 6 月份台灣就有超過 100 位醫師接受訓練。重要的青少年(teen)區隔方面,第二季全球 Invisalign 病例總數年增 20%,反映 11 至 19 歲青少年對 Invisalign 治療的持續採用。
We typically began to see an increase in teen case [starts] in late Q2 as more teens go into treatment during the summer timeframe in North America. Teen volume grew 19% year-over-year among our North American orthodontists. In addition, we continue to make progress internationally among teenagers where we had 35% year-over-year growth. In Q2 in APAC for example, we held a teens forum for the Australia and New Zealand markets where 200 doctors attended which was twice what we expected. We also participated in a separate teen forum sponsored by SiChuan University. On a 12-month basis, 155,000 teens started orthodontic treatment with Invisalign with an average age of 15 years old. Our investments in the teen segment continue. As discussed at our Investor Day last month we are currently developing products that will [span] Invisalign applicability over the next two or three years enabling our doctors to treat more teen patients and address younger kids for the first time.
我們通常在第二季末開始看到青少年病例 [starts] 增加,因為北美在暑期期間會有更多青少年開始治療。北美矯正專科醫師的青少年量能年增 19%。此外,我們在國際青少年市場也持續取得進展,年增 35%。例如在第二季 APAC,我們為澳洲與紐西蘭市場舉辦青少年論壇,有 200 位醫師出席,是我們預期的兩倍。我們也參與了由四川大學主辦的另一場青少年論壇。以 12 個月為基礎,有 155,000 名青少年開始使用 Invisalign 進行矯正治療,平均年齡為 15 歲。我們對青少年區隔的投資仍在持續。如同我們上月投資人日所討論,我們目前正在開發產品,將在未來兩到三年擴大 Invisalign 的適用範圍,使醫師能治療更多青少年患者,並首次能夠觸及更年幼的孩童。
Specifically, we will preview a mandibular repositioning product for teen Class II correction as well as our prototype, palate [expansion] used for Phase I treatment. With these additional offerings and features, we'll give our doctors a complete set of clear and removable appliances capable of any orthodontic treatment for patients of all ages.
具體而言,我們將預覽一款用於青少年第二類咬合(Class II)矯正的下顎重定位產品,以及我們的原型——用於第一期(Phase I)治療的顎 [expansion](擴弓)裝置。透過這些額外的產品與功能,我們將為醫師提供一整套透明且可拆卸的矯治裝置,能夠為各年齡層患者提供任何矯正治療。
Our integrated consumer marketing campaigns in North America, EMEA and APAC leveraged traditional paid media, [search] digital market, PR and social media to engage consumers at every point in the consumer purchase journey. Consumer interest and demand for Invisalign treatment continues to grow. In North America a key focus area for Q2 was sharing the stories of real patients who have used Invisalign treatment to improve their smile. These patient's stories have driven high consumer engagement with 136,000 video views. New program launches included an partisan -- a partnership with Bravo TV on a network that reaches millions of women who could benefit from Invisalign treatment. The Bravo integration weaves Invisalign treatment into the storyline of the hit show Odd Mom Out.
我們在北美、EMEA 與 APAC 的整合式消費者行銷活動,結合傳統付費媒體、[search] 數位行銷、公關與社群媒體,在消費者購買旅程的每個接觸點與消費者互動。消費者對 Invisalign 治療的興趣與需求持續成長。在北美,第二季的一個重點是分享真實患者使用 Invisalign 改善笑容的故事。這些患者故事帶來高度消費者互動,影片觀看次數達 136,000 次。新方案的推出包括與 Bravo TV 的合作——該電視網觸及數百萬名可能受益於 Invisalign 治療的女性。Bravo 的整合把 Invisalign 治療融入熱門影集《Odd Mom Out》的劇情之中。
In EMEA we focus primarily on the Real Patient campaign which continues to drive interest for Invisalign treatment online with web visits growing 112% compared to the same period last year. In Asia-Pacific new consumer campaigns kicked off in China and Australia and New Zealand and programs continued in Hong Kong and Japan to drive consumer awareness and patient demand.
在 EMEA,我們主要聚焦於「真實患者」(Real Patient)活動,持續推動線上對 Invisalign 治療的興趣,網站造訪量較去年同期成長 112%。在亞太地區,新的消費者活動已在中國以及澳洲與紐西蘭啟動,並在香港與日本延續既有方案,以提升消費者認知並帶動患者需求。
In Q3 we're planning a big bang consumer campaign in China which will leverage Paris Fashion Week. In Q2 our scanners business revenues were up 36% sequentially and up nearly 200% year-over-year reflecting a record number of units shipped in the quarter. Demand for the iTero Element scanner continues to expand fueled by primarily North American customers. This past March we began shipping the iTero Element for restorative workflows to customers who had preordered and were awaiting the new iTero Element. In EMEA we received a record number of iTero contracts and in APAC we received strong orders upon launching iTero Element at our Invisalign APAC Summit in May. We continue to work through a backlog of iTero Element scanners which remain at roughly six-months lead time as demand for our industry leading intraoral [scanners] continue.
第三季我們計畫在中國推出一個「大爆發」式的消費者活動,將結合巴黎時裝週。第二季我們的掃描器業務營收季增 36%,年增近 200%,反映本季出貨台數創新高。iTero Element 掃描器需求持續擴大,主要由北美客戶帶動。今年 3 月我們開始向已預購並等待新款 iTero Element 的客戶出貨用於修復(restorative)工作流程的 iTero Element。在 EMEA,我們取得創紀錄數量的 iTero 合約;在 APAC,我們於 5 月在 Invisalign APAC 高峰會推出 iTero Element 後也收到強勁訂單。我們仍在消化 iTero Element 掃描器的積壓訂單,交期仍約為 6 個月,因為市場對我們業界領先的口內 [scanners](掃描器)需求持續。
Use of iTero scanners for Invisalign case submissions [in place with] PVS impressions continue to expand. The Q2 total Invisalign cases submitted with a digital scanner worldwide increased 37.4% which reflects a record 46.4% for North America and 20.5% from international doctors. While these scans are predominantly from our iTero scanner, we are also seeing some uptick from 3M's True Def and Sirona's Omnicam; the other two third-party digital scanners that are qualified for Invisalign case submission.
以 iTero 掃描儀提交 Invisalign 病例(取代)PVS 印模的使用持續擴大。第二季全球以數位掃描儀提交的 Invisalign 病例總數增加 37.4%,其中北美創下 46.4% 的紀錄,國際醫師提交量增加 20.5%。雖然這些掃描主要來自我們的 iTero 掃描儀,但我們也看到來自 3M 的 True Def 與 Sirona 的 Omnicam 的使用略有上升;這兩款是另外兩種符合 Invisalign 病例提交資格的第三方數位掃描儀。
Before I turn the call over to David for our financial review, I want to talk to you about a supplier agreement we announced today with SmileDirectClub for their doctor-directed at-home aligner program for minor tooth movement. The field of orthodontics and dentistry had changed tremendously in two decades since Align Technology was founded. Many of the greatest changes we have been and continue to be driven mass customized clear aligners, 3D treatment planning, restorations, digital photography, x-rays, scanning, laser therapy, practice management, software and mobile devices; the list can go on and on. Technology has changed the demand of potential patients as well. The Internet, ecommerce and social media get consumers access to more information and more options for every type of treatment and procedure including where and when they want it and at costs much lower than traditional options.
在我把電話交給 David 進行財務回顧之前,我想先和各位談談我們今天宣布與 SmileDirectClub 達成的一項供應商協議,該協議用於其由醫師主導的居家牙套(輕微牙齒移動)計畫。自 Align Technology 成立以來的二十年間,齒顎矯正與牙科領域已發生巨大變化。許多最重大的改變過去由、且仍持續由大量客製化的透明牙套、3D 治療規劃、修復、數位攝影、X 光、掃描、雷射治療、診所管理、軟體與行動裝置等所驅動;清單還可以一直列下去。科技也改變了潛在患者的需求。網際網路、電子商務與社群媒體讓消費者能取得更多資訊與更多選擇,涵蓋各類治療與處置,包括他們想在何處、何時接受治療,以及以遠低於傳統選項的成本取得服務。
We've been watching the intersection of these technology advances and changes in consumer behavior and particularly we attracted different approaches to at-home teeth straightening with Clear Aligner. I'm talking specifically about doctor directed treatment shipped directly to consumers, not consumers trying to treat themselves in a do-it-yourself fashion.
我們一直在觀察這些科技進步與消費者行為改變的交會點,尤其關注以透明牙套進行居家牙齒矯正的不同做法。我特別指的是由醫師主導、直接寄送給消費者的治療,而不是消費者以 DIY(自己動手)方式嘗試自行治療。
The at-home model follows an established trend of direct-to-consumer, ship-to-home options for eyeglasses, contact lenses, hearing aids and more. Logically, this type of at home treatment in orthodontics is only possible with Clear Aligner and as the leader in Clear Aligner technology, we believe Align has to participate in and help shape this evolving market.
居家模式延續了既有的趨勢:直接面向消費者(direct-to-consumer)、寄送到府的選項已在眼鏡、隱形眼鏡、助聽器等領域普及。從邏輯上看,齒顎矯正領域的這類居家治療只有在透明牙套的條件下才可行;而作為透明牙套技術的領導者,我們相信 Align 必須參與並協助塑造這個正在演進的市場。
Emerging leader in this market is SmileDirectClub. It's a privately owned business based in Nashville, Tennessee. They were founded in 2013 and are doing business in 49 out of 50 states so far. Potential patients can either visit a Smile shop to get scanned, schedule an in-home scanning appointment or submit photos and impressions online to begin the evaluation process.
此市場的新興領導者是 SmileDirectClub。這是一家位於田納西州納什維爾的私人企業,成立於 2013 年,目前已在 50 個州中的 49 個州開展業務。潛在患者可以前往 Smile 門市進行掃描、預約到府掃描,或在線上提交照片與印模以開始評估流程。
SmileDirectClub offers a device for cosmetic treatment that includes up to 20-stages with no attachments and no IPR, interproximal reduction, primarily for adults with permanent dentition. They have a network of remote licensed orthodontists and general practitioner dentists who evaluate, review and approve the patient treatment and monitor progress of a case throughout treatment. In a separate release today we announced a supplier agreement with SmileDirectClub. Specifically, Align will provide a digital case setup which is made available on SmileDirectClub's Smile Check Portal. A SmileDirectClub licensed orthodontist or general dentist will review and approve the treatment and Align will then manufacturer aligners and ship them directly to SmileDirectClub.
SmileDirectClub 提供一種用於美容性治療的裝置,最多包含 20 個階段,不使用附件(attachments),也不進行 IPR(interproximal reduction,鄰面去釉/鄰接面削減),主要面向具有恆牙列的成人。他們擁有一個遠端持照的矯正專科醫師與一般牙科醫師網絡,負責評估、審查並核准患者治療,並在整個療程中監測病例進展。我們今天在另一份新聞稿中宣布與 SmileDirectClub 達成供應商協議。具體而言,Align 將提供數位病例設置(digital case setup),並在 SmileDirectClub 的 Smile Check Portal 上提供。SmileDirectClub 的持照矯正醫師或一般牙醫將審查並核准治療,之後 Align 將製造牙套並直接出貨給 SmileDirectClub。
These aligners will be manufactured per SmileDirectClub specification which does not include attachments and IPR. To be clear, this is not Invisalign. Invisalign brand and system of Clear Aligners will not be used for this kind of direct-to-consumer market. Invisalign system requires in-office doctor involvement throughout the course of treatment and will only be made available from an Invisalign provider.
這些牙套將依 SmileDirectClub 的規格製造,其中不包含附件與 IPR。需要說明的是,這不是 Invisalign。Invisalign 品牌與透明牙套系統不會用於此類直接面向消費者的市場。Invisalign 系統在整個療程中需要診所內醫師的參與,且僅會透過 Invisalign 供應醫師提供。
At Align we're investing nearly $100 million in R&D and marketing to further advance the science and technology for our Invisalign brand, the most advanced Clear Aligners in the world so our doctors can continue to achieve great outcomes for their patients. We will continue to [pass] the innovation we have delivered over the last 20 years [to] further advance of science and technology through our Invisalign doctors with new products such as Class III, teen Class II (inaudible) and Phase I palate expander that we indicated again recently in -- that will be available in 2017. These type of Invisalign [advances] will significantly increase the applicability of Invisalign Clear Aligners to our in-office doctors.
在 Align,我們投入近 1 億美元於研發與行銷,以進一步推進我們 Invisalign 品牌(全球最先進的透明牙套)的科學與技術,讓醫師能持續為患者達成優異的治療成果。我們將持續把過去 20 年所交付的創新,透過 Invisalign 醫師進一步推進科學與技術,並推出新產品,例如 Class III、青少年 Class II(聽不清)以及第一期顎腭擴弓器(Phase I palate expander),我們近期也再次提到——這些將於 2017 年推出。這類 Invisalign 的[進展]將大幅提升 Invisalign 透明牙套對診所內醫師的適用性。
The goal of our agreement with SmileDirectClub is to help expand the market and opportunity for Invisalign doctors while supporting SmileDirectClub's effort -- SmileDirectClub protocol is described which means we expect there to be little cannibalization of the existing market.
我們與 SmileDirectClub 協議的目標,是在支持 SmileDirectClub 推動其努力的同時,協助擴大市場並為 Invisalign 醫師帶來更多機會——SmileDirectClub 的治療規範已如前所述,因此我們預期對既有市場的侵蝕(cannibalization)將很有限。
In addition, we are creating a new Invisalign doctor referral program similar to our Invisalign Doc Locator that will ensure that the 30% of SmileDirectClub potential patients that did not fit these protocols and who are interested in straightening their teeth will be channeled back to existing Invisalign in-office doctors.
此外,我們正在建立一個新的 Invisalign 醫師轉介計畫,類似於我們的 Invisalign Doc Locator,以確保約 30% 不符合 SmileDirectClub 相關規範、但有意矯正牙齒的潛在患者,會被導回既有的 Invisalign 診所內醫師。
The process will work like this. Beginning in October we will create a new (inaudible) doctor referral program much like our Doc Locator works today. Consumers will request the SMILECHECK Case Assessment from SmileDirectClub but whose cases outside of their treatment scope will be systematically referred to an Invisalign provider in the area.
流程將如下運作。自 10 月起,我們將建立一個新的(聽不清)醫師轉介計畫,運作方式與目前的 Doc Locator 類似。消費者將向 SmileDirectClub 申請 SMILECHECK 病例評估(Case Assessment),但若其病例超出 SmileDirectClub 的治療範圍,系統將自動轉介至當地的 Invisalign 供應醫師。
We believe this will provide incremental growth opportunities for Invisalgin doctors by connecting them with new potential patients that would not have sought treatment otherwise.
我們相信,透過將 Invisalign 醫師與原本不會尋求治療的新潛在患者連結起來,這將為 Invisalign 醫師帶來額外的成長機會。
The at-home direct-to-consumer market is growing rapidly and while it's still very small today we believe the incremental growth potential that the [student] market represents is compelling; providing consumers who had very simple malocclusions with access to more affordable treatment from the convenience of their own home is accelerating and will only expand the overall market for orthodontic treatment. With that I'll now turn the call over to David.
居家、直接面向消費者的市場正在快速成長;雖然目前規模仍很小,但我們認為該[student]市場所代表的增量成長潛力相當吸引人。讓咬合不正非常輕微的消費者,能以更可負擔的方式、在自家便利地取得治療,正加速發展,並將只會進一步擴大整體齒顎矯正治療市場。接下來我把電話交給 David。
David White - CFO
David White - CFO
Thanks Joe. Let's review our second quarter financial results. Revenue for the second quarter was $269.4 million, up 12.8% from the prior quarter and up 28.6% from the corresponding quarter a year ago. Second quarter Clear Aligner revenue of $243.4 million was up 10.8% sequentially and up 21.2% year-over-year. The sequential revenue increase was primarily related to increased Clear Aligner volumes and to a lesser extent our price increase in North America.
謝謝 Joe。讓我們回顧第二季財務結果。第二季營收為 2.694 億美元,較前一季成長 12.8%,較去年同期成長 28.6%。第二季透明牙套(Clear Aligner)營收為 2.434 億美元,較前一季成長 10.8%,較去年同期成長 21.2%。營收的季增主要與透明牙套出貨量增加有關,此外北美的價格上調亦有部分貢獻。
On a year-over-year comparative basis the growth rate for both total revenue and Clear Aligner revenue was lower by approximately four points related to the additional Aligner policy change we implemented in July of last year. Q2 ASP's were up sequentially from Q1 about $30.00 reflecting a price increase in the U.S. as well as favorable foreign exchange rates.
以年對年比較來看,總營收與透明牙套營收的成長率皆因我們去年 7 月實施的額外牙套(Additional Aligner)政策變更而約低了 4 個百分點。第二季 ASP(平均銷售單價)較第一季季增約 30 美元,反映美國的價格上調以及有利的外匯匯率變動。
Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels and geographies as well as our price increase in North America and international. These increases were partially offset by lower ASP's primarily related to the additional Aligner policy change made last year. For the second quarter, total Invisalign shipments of 177,000 cases were up 8.1% sequentially reflecting growth from both our international and North America customers. Year-over-year case volume growth was 22.4% driven by growth across all regions.
我們的年對年營收成長,反映 Invisalign 病例量在所有客戶通路與各地區的成長,以及北美與國際市場的價格上調。上述增幅部分被 ASP 下降所抵銷,而 ASP 下降主要與去年所做的額外牙套政策變更有關。第二季 Invisalign 總出貨量為 177,000 例,較前一季成長 8.1%,反映國際與北美客戶皆有成長。年對年病例量成長為 22.4%,由各區域的成長所帶動。
For North American orthodontists, Q2 Invisalign case volume was up 4.7% sequentially reflecting higher adoption and utilization rates across the channel and up 20% year-over-year. For North American GP dentists, case volume was up 3% sequentially and up roughly 10% year-over-year reflecting continued solid performance from mid high volume GP's offset somewhat by our large base of lower volume GP's.
就北美矯正專科醫師而言,第二季 Invisalign 病例量較前一季成長 4.7%,反映該通路的採用率與使用率提升;年對年成長 20%。就北美一般牙科醫師(GP dentists)而言,病例量較前一季成長 3%,年對年約成長 10%,反映中高量 GP 持續穩健表現,但部分被我們龐大的低量 GP 基礎所抵銷。
For international doctors, Invisalign case volume was up 16.8% sequentially and up 38.3% year-over-year reflecting increased adopters and utilization.
就國際醫師而言,Invisalign 病例量較前一季成長 16.8%,年對年成長 38.3%,反映採用醫師數增加以及使用率提升。
Worldwide Invisalign utilization in Q2 was 5.1 cases per doctor, up from 4.6 in Q2 last year. North America ortho utilization was a record 10.7, up from 9.5 in the prior year. North America GP utilization was 3.1, up from 3.0 in the prior year and international utilization was 5.0, also a record up from 4.6 cases per doctor in Q2 last year driven primarily but increased utilization in EMEA which was a record 5.5 cases per doctor in Q2 compared to 4.8 cases a year ago.
第二季全球 Invisalign 使用率為每位醫師 5.1 例,高於去年第二季的 4.6。北美矯正專科(ortho)使用率創新高達 10.7,高於前一年同期的 9.5。北美一般牙科(GP)使用率為 3.1,高於前一年同期的 3.0;國際使用率為 5.0,同樣創新高,高於去年第二季每位醫師 4.6 例,主要由於 EMEA 地區使用率提升所帶動;EMEA 第二季每位醫師 5.5 例亦創新高,較一年前的 4.8 例增加。
In Q2 we added 2885 new Invisalign doctors worldwide; 1125 of which were new North American doctors and 1760 of which were new international doctors. This compares to 2470 in Q1 and 2455 in the same quarter last year. Our scanner and services revenues for the second quarter were $26 million up 36.3% sequentially and up almost 200% year-over-year. As Joe mentioned, we began shipping the iTero Element for restorative workflow in Q2 and as a result almost half of the scanners shipped were for our GP customers who have been patiently waiting for their new iTero Element. We're pleased that the demand for scanners continues to be strong as we continue keeping pace with shipping, shipments.
第二季我們在全球新增 2,885 位 Invisalign 醫師;其中 1,125 位為北美新增醫師,1,760 位為國際新增醫師。相較之下,第一季為 2,470 位,去年同季為 2,455 位。第二季我們的掃描儀與服務營收為 2,600 萬美元,較前一季成長 36.3%,年增近 200%。如 Joe 所提到,我們在第二季開始出貨用於修復工作流程的 iTero Element,因此出貨的掃描儀中將近一半是提供給一直耐心等待新 iTero Element 的 GP 客戶。我們很高興掃描儀需求持續強勁,且我們也持續跟上出貨、出貨量。
Moving on to gross margin; second quarter overall gross margin was 76.2% slightly better than expected, up 0.5 sequentially and year-over-year. Clear Aligner gross margin for the second quarter was 78.6%, up 0.3 points both sequentially and year-over-year. The sequential increase was primarily driven by higher ASP's partially offset by seasonally higher training activity.
接著談毛利率;第二季整體毛利率為 76.2%,略優於預期,較前一季及去年同期各提高 0.5 個百分點。第二季透明牙套(Clear Aligner)毛利率為 78.6%,較前一季及去年同期各提高 0.3 個百分點。前一季到本季的提升主要由較高的 ASP(平均售價)帶動,但部分被季節性較高的培訓活動所抵銷。
Year-over-year gross margin increase primarily reflects the benefit from leverage of our fixed cost over higher case volumes partially offset by lower ASP's as a result of the additional liner policy. Q2 gross margin for our scanner segment was a record 53.6%, up 8.6 points sequentially and 38.6 points year-over-year.
年增毛利率的提升主要反映在較高病例量下固定成本攤提效益(槓桿效應),但部分被因額外內襯(liner)政策而導致的較低 ASP 所抵銷。第二季我們掃描儀事業部毛利率創新高達 53.6%,較前一季提高 8.6 個百分點,較去年同期提高 38.6 個百分點。
Both the sequential and year-over-year increases in gross margin were primarily a result of higher ASP's and the lower manufacturing costs of our iTero Element scanner. Q2 operating expenses were $140.1 million, up sequentially by $12.8 million or 10% primarily due to a full quarter of employed compensation related costs such as annual wage increases, stock-based compensation awards and new hires as well as go-to-market investments. Q2 operating expenses were lower, however, than our outlook due primarily to slower higher and investments in sales territory coverage, same go-to-market activities that were delayed in the second half of the year and more ERP costs being capitalized and anticipated during the quarter.
毛利率無論季增或年增,主要皆因 ASP 較高以及 iTero Element 掃描儀製造成本較低所致。第二季營業費用為 1.401 億美元,較前一季增加 1,280 萬美元或 10%,主要因員工薪酬相關成本(如年度加薪、以股票為基礎之薪酬獎勵與新進人員)完整反映一整季,以及市場推進(go-to-market)投資所致。不過,第二季營業費用低於我們的展望,主要因招募與銷售區域覆蓋投資進度較慢、部分原定於下半年進行的同類 go-to-market 活動延後,以及本季資本化的 ERP 成本高於預期。
On a year-over-year basis, Q2 operating expenses were up $23.8 million or 20.4% reflecting increased headcount and continued investment in our go-to-market activities incidental to the growth of our business as well as our ERP implementation project.
以年對年來看,第二季營業費用增加 2,380 萬美元或 20.4%,反映人員編制增加,以及隨著業務成長持續投入 go-to-market 活動,並包含我們的 ERP 導入專案。
Operating margin, our second quarter operating margin was 24.2%, up 1.9 points sequentially and up four points year-over-year. The sequential increase in operating margin reflects primarily, relates primarily, to higher Clear Aligner volumes and higher gross margins overall. On a year-over-year basis, Q2 operating margin was impacted by 2.3 points on the additional liner policy change.
營業利益率方面,第二季營業利益率為 24.2%,較前一季提高 1.9 個百分點,較去年同期提高 4 個百分點。營業利益率的季增主要(主要是)來自透明牙套出貨量增加以及整體毛利率提升。年對年而言,第二季營業利益率受到額外內襯政策變更影響 2.3 個百分點。
With regards to our second quarter tax provision, our tax rate was 23.2% compared to 23.4% in Q1 2016. Second quarter diluted earnings per share was $0.62 compared to $0.50 reported in Q1 and $0.39 reported in the same quarter last year.
就第二季所得稅費用而言,我們的有效稅率為 23.2%,相較 2016 年第一季的 23.4%。第二季稀釋後每股盈餘為 0.62 美元,相較第一季的 0.50 美元,以及去年同季的 0.39 美元。
Moving on to the balance sheet. Capital expenditures for the second quarter were $18.8 million primarily relating to equipment purchases to expand our manufacturing capacity in Juarez, Mexico and our ERP implementation.
接著看資產負債表。第二季資本支出為 1,880 萬美元,主要用於購置設備以擴增墨西哥華雷斯(Juarez)的製造產能,以及 ERP 導入。
Cash flow from operations for the second quarter was $76.20 million and free cash flow for the second quarter, defined as cash flow from operations less capital expenditures, amounted to $57.3 million.
第二季營運活動現金流為 7,620 萬美元;第二季自由現金流(定義為營運活動現金流減資本支出)為 5,730 萬美元。
During the quarter, as a part of our $300 million April 2014 stock repurchase program, we entered into an accelerated stock repurchase agreement to repurchase $50 million of our common stock under which we paid $50 million and received an initial delivery of approximately half a million shares based on current market prices. The final (inaudible) shares is scheduled for October and a number of shares will be based on our volume weighted average stock price during the term of the ASR less an agreed upon discount. Upon completion of the ASR we will commence the repurchase of $50 million of our common stock on the open market. These two actions together will complete our April 2014 stock repurchase program.
本季期間,作為我們 2014 年 4 月 3 億美元庫藏股回購計畫的一部分,我們簽訂加速庫藏股回購(ASR)協議以回購 5,000 萬美元普通股;依該協議我們支付 5,000 萬美元,並按當前市價先行交付約 50 萬股、約為一半的股份。最終(聽不清)股份預計於 10 月交付,股份數將以 ASR 期間的成交量加權平均股價(VWAP)扣除約定折價後計算。ASR 完成後,我們將在公開市場開始回購 5,000 萬美元普通股。上述兩項行動合計將完成我們 2014 年 4 月的庫藏股回購計畫。
Cash, cash equivalents and marketable securities, included both short and long-term investments were $685 million. This compared to $678.7 million at the end of 2015, an increase of approximately $6.3 million. Lastly I wanted to comment on our ERP implementation which went live the first week of July. Over the past year plus our team has worked very hard to ensure successful data migration and integration of new systems and processes. Overall, our implementation went very smoothly. Given the magnitude of this process, [new] project, we're continuing to monitor and troubleshoot potential issues but at this time believe we are past any potential for significant business disruption.
現金、約當現金與有價證券(包含短期與長期投資)為 6.85 億美元。相較 2015 年底的 6.787 億美元,約增加 630 萬美元。最後我想評論我們的 ERP 導入,該系統已於 7 月第一週上線。過去一年多來,我們的團隊非常努力以確保資料移轉成功並整合新系統與流程。整體而言,導入進行得非常順利。鑑於此流程、[新的] 專案規模,我們仍持續監控並排除潛在問題,但目前我們相信已經度過任何可能造成重大業務中斷的風險。
We're pleased to have a foundation that enables new capabilities, improves our speed of execution and will be used to improve our customers experience. As part of this implementation, we also implemented a legal restructuring of our subsidiary relationships which will return an excess of $100 million of cash to the U.S. tax free in Q3.
我們很高興擁有可支撐新能力的基礎,能提升執行速度,並將用於改善客戶體驗。作為此導入的一部分,我們也完成子公司關係的法律重組,將在第三季把超過 1 億美元的現金免稅匯回美國。
As Joe mentioned earlier, in October we'll begin supplying aligners to SmileDirectClub's Aligner Program for minor tooth movements. As part of this transaction, Align acquired a 17% stake in SmileDirectClub for $46.7 million and gained a seat on SmileDirectClub's board of directors. As a result of our equity holding in SmileDirectClub, Align is required to account for this investment under the equity method of accounting. Thus, Align will include proportional share of SmileDirectClub's earnings or losses in it's financial statements beginning July 25, 2016.
如 Joe 先前提到,10 月我們將開始為 SmileDirectClub 的 Aligner Program 供應用於輕微牙齒移動的牙套。作為此交易的一部分,Align 以 4,670 萬美元取得 SmileDirectClub 17% 的股權,並獲得 SmileDirectClub 董事會席次。由於我們持有 SmileDirectClub 的股權,Align 需依權益法(equity method)對該投資進行會計處理。因此,自 2016 年 7 月 25 日起,Align 將在財務報表中納入按持股比例計算的 SmileDirectClub 盈利或虧損。
Our financial results will reflect two components; commencing in October when we begin to supply aligners, the sale of aligners to SmileDirectClub and the income there from under the supply agreement which will be reported in our Clear Aligner business segment and in Q3, and going forward, our portion of SmileDirectClub's reported profits and/or losses will be included in our operating expenses.
我們的財務結果將反映兩個組成部分;自 10 月起我們開始供應牙套時,將認列對 SmileDirectClub 的牙套銷售,以及依供應協議取得的相關收入,並將在我們的透明牙套(Clear Aligner)業務部門中報告;此外,自第三季起並在未來持續,我們按比例分攤的 SmileDirectClub 所報告之利潤及/或虧損,將納入我們的營業費用。
We are excited about this incremental new market opportunity and the potential for our Invisalign doctors to benefit from an untapped segment of consumers with minor malocclusion who want a better smile. We anticipate this relationship will be incremental to our top-line revenue and earnings in 2017.
我們對這項新增的市場機會感到振奮,也看好我們的 Invisalign 醫師可望受惠於一個尚未被開發的消費者族群:具有輕微咬合不正、希望擁有更好笑容的消費者。我們預期此合作關係將在 2017 年為我們的營收與獲利帶來增量貢獻。
With that, let's now turn to our business outlook and the factors that inform our view starting with the demand outlook. As we head into the summer months and busy teen season, we expect to increase, an increase, of [teen starts, case] starts among our North America orthos. Our North American GP's typically have a seasonally slower quarter in Q3. Overall, we're expecting North America volumes to be seasonally down quarter-over-quarter. In our international markets our European doctors typically spend fewer days in the office due to summer vacations and extended holidays.
接下來我們轉向業務展望,以及支撐我們觀點的因素,首先從需求展望談起。進入夏季月份與青少年旺季時,我們預期北美矯正專科的青少年起始病例(teen starts、case starts)將增加。北美 GP 在第三季通常會有季節性較慢的一季。整體而言,我們預期北美出貨量將因季節性因素而較前一季下滑。在國際市場方面,歐洲醫師通常因暑假與延長假期而在診所出勤天數較少。
Our Asia Pacific region continues to grow and is beginning to offset some of the seasonality we typically experience in our European countries. We therefore anticipate international Invisalign (inaudible) to be flat to sequentially up from Q2. For our Scanner business, we expect scanner shipments to be up sequentially as the iTero Element continues to penetrate the market. We estimate the Q3 impact of the SmileDirectClub transaction will reduce diluted EPS by less than $0.01 per share.
我們的亞太地區持續成長,並開始抵銷我們在歐洲國家通常會經歷的部分季節性影響。因此,我們預期國際 Invisalign(聽不清)將與第二季持平至較前一季小幅成長。就掃描儀業務而言,隨著 iTero Element 持續滲透市場,我們預期掃描儀出貨量將較前一季增加。我們估計 SmileDirectClub 交易對第三季的影響,將使稀釋後每股盈餘減少低於每股 0.01 美元。
With this as a backdrop, we expect the third quarter to shape up as follows: Invisalign case volume is anticipated to be in the range of 174.2 to 176.9 thousand cases, up approximately 18.1% to 19.9% over the same period a year-ago.
在此背景下,我們預期第三季將呈現如下走勢:Invisalign 病例量預計介於 174.2 至 176.9 千例之間,較去年同期約成長 18.1% 至 19.9%。
We expect Q3 net revenues to be in the range of $267.2 million to $273.5 million. We expect Q3 gross margin to be in the range of 74.4% to 74.8%, down sequentially primarily due to increased mix of scanner business and continuous investment in international manufacturing expansion.
我們預期第三季淨營收介於 2.672 億美元至 2.735 億美元之間。我們預期第三季毛利率介於 74.4% 至 74.8% 之間,較前一季下滑,主要係因掃描器業務占比提高,以及持續投資於國際製造產能擴張。
We expect Q3 operating expenses to be in the range of $147.1 million to $148.1 million, up quarter-over-quarter primarily due to hiring, delayed marketing investments as previously mentioned and higher ERP expenses as the cost of the last implementation phase, [call] stabilization are not capitalized. Our Q3 operating margin should be in the range of 19.3% to 20.6%. Our effective tax rate should be approximately 24.5% and diluted shares outstanding should be approximately $81.4 million exclusive of any share repurchases.
我們預期第三季營業費用介於 1.471 億美元至 1.481 億美元之間,較前一季增加,主要由於招募人員、如先前所提及的延後行銷投資,以及 ERP 費用較高,因最後一個導入階段的成本與(系統)穩定化並未資本化。我們第三季營業利益率應介於 19.3% 至 20.6% 之間。我們的有效稅率應約為 24.5%,稀釋後流通在外股數應約為 8,140 萬股(不含任何庫藏股回購)。
Taken together, we expect our Q3 diluted EPS to be in the range of $0.49 to $0.52.
綜合以上,我們預期第三季稀釋後每股盈餘(EPS)介於 0.49 美元至 0.52 美元之間。
With that, I'll turn the time back over to Joe for final comments. Joe?
接下來,我把時間交回給 Joe 做最後的評論。Joe?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Thanks, David. Exciting time for Align Technology; demand and adoption of our Invisalign system continues to expand across all of our regions and with each new Invisalign innovation doctors are doing more and more with Clear Aligners and growing their practices. Today we announced a supply agreement with SmileDirectClub so we'll provide access to Clear Aligner treatment to more consumers than before while providing Align with an incremental revenue opportunity and helping us connect Invisalign providers with a new base of potential patients.
謝謝你,David。對 Align Technology 而言,這是令人振奮的時刻;我們 Invisalign 系統的需求與採用度持續在各區域擴大,且隨著每一項新的 Invisalign 創新,醫師使用透明牙套(Clear Aligners)能做的治療越來越多,並帶動其診所成長。今天我們宣布與 SmileDirectClub 達成供應協議,因此我們將讓更多消費者比以往更容易取得透明牙套治療,同時為 Align 帶來額外的營收機會,並協助我們把 Invisalign 服務提供者與一批新的潛在病患族群連結起來。
Thanks for your time today, I'll now open the call for your questions. Operator?
謝謝各位今天撥冗參與,接下來我將開放提問。接線員?
Operator
Operator
Thank you. (Operator instructions.) One moment please while we poll for questions. The first question today comes from Robert Jones of Goldman Sachs, please go ahead.
謝謝。(接線員指示。)請稍候,我們正在收集問題。今天第一個問題來自高盛(Goldman Sachs)的 Robert Jones,請開始。
Robert Jones - Analyst
Robert Jones - Analyst
Thanks for the questions. Most of the metrics in the quarter were ahead of your own guidance and ahead of our expectations. I guess one exception relative to us at least was North American cases and in particular case growth with GP's. So I guess I'm just curious, how did the 10% case growth in North American GP's compare with your own internal expectations and then just related to that, any view of what you can do or what you're doing that could reaccelerate growth in that group in the back half?
謝謝讓我提問。本季多數指標都優於你們自己的財測指引,也優於我們的預期。我想相對於我們而言,唯一的例外是北美病例數,尤其是一般牙醫(GP)的病例成長。因此我想請教,北美 GP 病例 10% 的成長,與你們內部預期相比如何?另外相關地,在下半年你們認為可以做什麼、或正在做什麼,以重新加速該族群的成長?
David White - CFO
David White - CFO
Yeah Bob, David. If you look at our business in North America and you compare that growth relative to the last few years we feel like our North America business is really taking a nice uptick this year and starting last year with many of the investments we made. We think it's still strong on both the ortho and the GP side where we're continuing to see at record or near record utilization amongst those classes of doctors. We still are challenged, you know, when it comes to low stage doctors, particularly low submitting GP's who engage with us one quarter and then maybe don't engage the next quarter. And so we struggle at times trying to reach those doctors and we've continued to invest in various go-to-market strategies that will engage them more fully with us but it does represent a challenge for us in terms of how we forecast those doctors in any particular quarter.
是的 Bob,我是 David。若你看我們北美業務,並將其成長與過去幾年相比,我們覺得今年北美業務確實有相當不錯的上升動能,而這股動能從去年開始,與我們所做的多項投資有關。我們認為無論在矯正專科(ortho)或 GP 端都仍然強勁,我們持續看到這些醫師族群的使用率達到或接近歷史新高。不過我們仍面臨挑戰,主要在於低階段(low stage)醫師,特別是低提交量的 GP;他們可能某一季與我們合作,下一季又不合作。因此我們有時在觸及這些醫師上會遇到困難;我們也持續投資各種市場進入(go-to-market)策略,以更全面地讓他們與我們互動,但這確實在我們如何預測任何特定季度的這些醫師表現上,構成挑戰。
The other thing I would just mention is that when you look at our comps, particularly in the second quarter year-over-year, you'll remember that Q2 a year ago we had -- we were running an E5, an E10 promotion at that point in time which we're not running this year and so when you look at last year Q2, we had a very strong quarter from a case volume standpoint because of those promotions on those low stage products as well as the fact that we had additional Aligner program that was, you might say, an easier qualification bar for the doctors to qualify for. And, when you look at those two they have a bigger impact on our year-over-year volume but certainly a lesser impact on a year-over-year revenue basis.
另外我想補充的是,當你看我們的比較基期,特別是第二季的年對年比較,你會記得去年第二季我們當時在做 E5、E10 的促銷活動,而今年沒有做。因此回看去年第二季,因為那些針對低階段產品的促銷,加上我們還有一個額外的 Aligner 計畫——你可以說那對醫師而言是較容易達到資格門檻的——所以從病例量角度看,去年第二季非常強勁。而當你把這兩項因素納入考量,它們對年對年病例量的影響更大,但對年對年營收的影響相對較小。
Robert Jones - Analyst
Robert Jones - Analyst
Okay, that all makes sense and I guess just one on the SmileDirectClub agreement. It sounds like you're saying it could be incremental to the P&L and in particular top-line next year. Anyway we could put a little bit more numbers around that, you know, maybe how many members do they have today, how many do you anticipate will show up at Invisalign dentists offices? Anything just directionally to help us as we think about layering that in would be really helpful.
好的,這些都合理。我想再問一個關於 SmileDirectClub 協議的問題。聽起來你們的意思是,它可能會對損益表帶來增量貢獻,尤其是明年的營收端。是否能提供一些更具體的數字,例如他們目前有多少會員、你們預期會有多少人會到 Invisalign 牙醫診所就診?任何方向性的資訊都會很有幫助,讓我們在建模時能把它納入考量。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Hi Bob, it's Joe Hogan, you know, we can tell by the announcement that that will start in October, we'll start shipping then. It's hard for us to really triangulate around what that might mean as we go into next year but we'll give you as much transparency as possible when we come back, the third quarter earnings announcement.
嗨 Bob,我是 Joe Hogan。從公告內容你也看得到,該合作將於 10 月開始,我們屆時會開始出貨。對我們而言,要精準推估這對明年可能意味著什麼其實很困難,但我們會在第三季財報公告時回來,盡可能提供最大的透明度。
Robert Jones - Analyst
Robert Jones - Analyst
Fair enough, thanks so much.
了解,非常感謝。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Okay.
好的。
Operator
Operator
The next question comes from Robert Willoughby of Credit Suisse, please go ahead.
下一個問題來自瑞士信貸(Credit Suisse)的 Robert Willoughby,請開始。
Robert Willoughby - Analyst
Robert Willoughby - Analyst
Same line of questioning I guess. Do you -- can you give us any sense of how much you think the SmileClub deal expands your total addressable market here? This looks previously untapped, do you have a size of the overall opportunity?
我想也是同一條線的問題。你們能否讓我們大概了解一下,你們認為 SmileClub 這筆交易會把你們的整體可服務市場(TAM)擴大多少?這看起來是先前未被觸及的市場,你們是否有整體機會規模的估計?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
You know, it's really hard for us to call the market. I mean, when you look at the run rate right now for SmileDirectClub, it's in the $50 million range. It has really been accelerating significantly over the last six months so it's really difficult to quantify this market. You can also see by the statistics that we threw out, you know, Rob, that this is a market that we really haven't serviced. It's less than 2% overlap with our current business. It's something that we're learning a lot from Doug and David, the key leaders in the business in exactly how this works so we're excited about it, we think we can help and make a good partnership. We're also excited about how we feel it can help our business too in the sense of referrals back that don't fit this protocol back to our Invisalign in doc's offices. But, again, this is brand new, it's hard for us to call it and we'll give you more data as it becomes more apparent and as we move into the supply agreement in October.
你知道,要我們去界定這個市場其實很難。我的意思是,若看 SmileDirectClub 目前的營運年化(run rate),大約在 5,000 萬美元的規模。過去六個月它的加速幅度非常顯著,因此很難量化這個市場。你也可以從我們提出的統計數據看到,Rob,這是一個我們過去幾乎沒有服務到的市場,與我們現有業務的重疊不到 2%。我們也正從 Doug 和 David——該業務的關鍵領導人——身上學到很多,了解這套模式究竟如何運作,所以我們對此感到興奮;我們認為我們能提供協助並建立良好的合作夥伴關係。我們也對它可能如何幫助我們的業務感到期待,因為那些不符合此一流程(protocol)的轉介,可能會回流到我們 Invisalign 醫師診所端。不過,這一切都非常新,我們很難現在就下定論;隨著 10 月供應協議啟動、情況更明朗時,我們會提供更多數據。
Robert Willoughby - Analyst
Robert Willoughby - Analyst
Maybe another factual question around it though, if they're kind of tracking along at a $50 million rate, I assume they're losing a little bit of money on that. Is that a safe bet?
不過再問一個事實性的問題:如果他們目前大致以 5,000 萬美元的速度在跑,我猜他們應該還在小幅虧損。這樣推測合理嗎?
David White - CFO
David White - CFO
Yeah, right now they'll be cash flow positive next year some time so this year they're still burning cash.
是的,他們預計在明年某個時間點會轉為現金流為正,所以今年仍在消耗現金。
Robert Willoughby - Analyst
Robert Willoughby - Analyst
Okay, and just how it works, is there a liability if the treatment goes bad, that goes back to an orthodontist somewhere, correct, that does not come to you and just the last one on SmileClub, is there a bad debt number associated with the business?
好的。再問一下運作方式:如果治療結果不佳,責任會回到某個地方的矯正醫師那邊,對嗎?不會回到你們這裡。最後一個關於 SmileClub 的問題:這個業務是否有相關的壞帳數字?
David White - CFO
David White - CFO
I'll take the latter part. As it relates to the bad debt part, they have a very small cancellation rate amongst the people that are qualified. So they go through a process where a person identifies themselves as having an interest in being treated, they're screened in multiple levels from both a photographer, from a photo standpoint as well as from a scan or an impression and assuming the person passes their protocols and is capable of being treated, they have a very small cancellation at that point in time.
我來回答後半段。就壞帳而言,在符合資格的人當中,他們的取消率非常低。他們有一套流程:先由個人表達有意願接受治療,接著會經過多層次篩選,包括從照片(攝影)角度的審核,以及掃描或印模;假設該個人通過其流程並適合接受治療,那麼在那個時間點的取消率就非常低。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
And Rob, on the question that you had about from a liability standpoint. Remember we're the supplier of these aligners. [SEC] -- will sell them to the customer, basically do it for their specifications. Our job is to make the cleanest best aligners we can based on those specifications. [SEC] obviously makes the transfer and something like that who has liability, obviously we all know in a lawsuit whoever has the deepest pockets are going to have some issues too but I think from a liability standpoint I think it's shared in that sense but I'll ask Roger to make a comment on it.
Rob,關於你提到的責任問題。請記得我們是這些牙套的供應商。[SEC]——會把產品賣給客戶,基本上是依照他們的規格來執行。我們的工作是依據那些規格製造出最乾淨、最好的牙套。[SEC] 顯然會進行交付;至於像那樣的情況由誰負責,顯然我們都知道在訴訟中「口袋最深」的一方也可能會面臨一些問題,但我認為就責任而言,在某種程度上是共同分擔的;不過我會請 Roger 對此再補充說明。
Roger George - VP, Legal Affairs and General Counsel
Roger George - VP, Legal Affairs and General Counsel
Hi, it's Roger George, General Counsel. The doctor is writing the prescription and is treating the patient. So, that's where they start. -- our common model.
嗨,我是總法律顧問 Roger George。醫師在開立處方並且在治療病患。所以,他們就是從那裡開始——我們共同的模式。
Robert Willoughby - Analyst
Robert Willoughby - Analyst
Thank you very much.
非常感謝。
Roger George - VP, Legal Affairs and General Counsel
Roger George - VP, Legal Affairs and General Counsel
Yep.
是的。
Operator
Operator
The next question comes from Brandon Couillard of Jeffries, please go ahead.
下一個問題來自 Jefferies 的 Brandon Couillard,請繼續。
Unidentified Participant
Unidentified Participant
Hi, (inaudible) in for Brandon. David, if we look back four years ago, [3 through 12] was one of the very few periods historically that Align has come short of its revenue guidance and at that time you pointed to noise around Olympic as well as a pullback in advertising activity because of the event. So I'm curious if you applied an extra dose of conservatism or not with respect to initial 3Q guidance for the upcoming Olympics and to which extent did you consider that factor, if at all?
嗨,(聽不清)我代替 Brandon。David,如果我們回顧四年前,[3 through 12] 是 Align 歷史上少數幾個營收指引落空的期間之一,當時你提到 Olympic 周邊的雜訊,以及因該事件導致廣告活動回落。所以我想了解的是,針對即將到來的奧運,你們在最初的第三季指引上是否額外採取了更保守的作法?以及你們在多大程度上(如果有的話)把這個因素納入考量?
David White - CFO
David White - CFO
Well, I wasn't here four years ago but I think that's an interesting causal, I haven't heard that one before since I've been here. I can tell you as it relates to our Q3 guidance that we've given today, that didn't enter into our thinking at all and we basically, you know, approached our guidance the way we typically approach it looking at the strength of the prior quarter, the doctor engagement, etc., and that particular factor wasn't considered.
嗯,我四年前不在這裡,但我覺得這個因果關係很有意思;自從我來之後,還沒聽過這個說法。我可以告訴你,就我們今天給出的第三季指引而言,這完全沒有納入我們的思考。我們基本上就是以我們一貫的方式來制定指引,觀察前一季的強勁程度、醫師端的參與度等等,而你提到的那個因素並未被考慮。
Unidentified Participant
Unidentified Participant
Got it, could you walk us through the impact of the [anniversary] of the Aligner policy change in the second half in both the revenues and P&L?
了解。你能否帶我們看一下下半年「矯正器」政策變更的[週年]影響,包含對營收與損益表(P&L)的影響?
David White - CFO
David White - CFO
So it continues to be a drag on earnings and it will be a drag on earnings for, as we said, a year ago for at least a couple of years as we work off those grandfathered cases. But starting in Q3 however, it won't be a drag on a year-over-year compare because we Q3 2015 was the first quarter in which we actually implemented that policy. So I think those -- we won't talk about it necessarily so much on a year-over-year basis but it still will be a drag to some extent.
所以它仍然會拖累獲利,而且正如我們一年前所說,至少在接下來幾年、我們把那些既有(grandfathered)案件消化完之前,它都會持續拖累獲利。不過從第三季開始,它在年對年比較上就不會再形成拖累,因為 2015 年第三季是我們實際開始實施該政策的第一個季度。所以我想——我們在年對年的角度可能不會再特別多談,但它在某種程度上仍會是個拖累。
Unidentified Participant
Unidentified Participant
Got it, thanks.
了解,謝謝。
Operator
Operator
The next question comes from Steve Beuchaw of Morgan Stanley, please go ahead.
下一個問題來自 Morgan Stanley 的 Steve Beuchaw,請繼續。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Hi, good afternoon and thanks for the time. Just a couple of little small housekeeping items. The ERP, I mean once we get to the fourth quarter can you give us a sense for what the swing is on opex between 3Q and 4Q just [from] online purposes, once we get passed that ramp?
嗨,午安,謝謝撥冗。我有幾個小的例行問題。關於 ERP,我是說,等我們到第四季時,你能否讓我們了解一下,營業費用(opex)在第三季與第四季之間的變動幅度大概是多少?就(聽不清)用途而言,當我們度過那段爬坡期之後。
David White - CFO
David White - CFO
Yeah, so Steve it's going to be a little bit up in Q2, about -- a little bit less than a couple of million dollars primarily as I indicated in my comments that the stabilization phase is not capitalizable. So that will -- that's an uptick in Q3 and when we get to Q4 we would expect that principally to reverse itself almost dollar for dollar as those costs begin to drop off.
可以。Steve,第三季會稍微增加一些,相較第二季大約——不到 200 萬美元,主要原因如我在評論中提到的,穩定化階段的成本是不能資本化的。所以那會——在第三季形成一個上升;而到了第四季,我們預期這部分基本上會幾乎一美元對一美元地回轉,因為那些成本會開始下降。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Okay, got it. And then just one Joe, reflecting back on your prepared remarks, probably the most positive I've heard you in your tone around third-party scanners and their contribution, I wonder if you could just expand upon that. What is it that you're seeing there that's incremental here and can you give us a sense for where you think volumes are headed there? Thanks.
好,了解。然後還有一個問題給 Joe,回到你事先準備的發言,你對第三方掃描器及其貢獻的語氣,可能是我聽過你最正面的。我想請你再多談一點。你看到的是什麼讓你覺得有新增的動能?以及你能否讓我們了解你認為那邊的量會往哪個方向走?謝謝。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Steve, you know, I think my enthusiasm is around just the scanners in general when you see the percent of scans we're getting right now that come into the organization approaching 50%. That means a lot to us from a quality standpoint in how we can deal with our customer base. So I think I interpret my enthusiasm more around just the scanning piece than it is third-party or whatever. Our scanning business obviously is having a really good year and we're projecting it to have a very strong ending this year too and it's not just selling scanners, it's just what it does, it reinforces from a customer base standpoint both with GP's and orthos and makes things easier for us and it gives us a wonderful platform in a sense to use that scanner for additional products making things easier for our customer base.
Steve,你知道,我的熱情其實是針對掃描器整體而言,因為你看到我們目前進到組織內的掃描比例接近 50%。從品質角度來看,這對我們在服務客戶群時意義重大。所以我對我自己的熱情解讀,更多是在掃描這件事本身,而不一定是第三方或其他。很明顯地,我們的掃描業務今年表現非常好,我們也預期今年年底會非常強勁;而且不只是賣掃描器而已,更重要的是它帶來的效果:從客戶基礎的角度,不論是一般牙醫(GP)或矯正專科(ortho),它都能強化黏著度、讓事情對我們更容易,也提供我們一個很棒的平台,某種意義上可以用這個掃描器去延伸更多產品,讓我們的客戶更省事。
As far as the third-party piece, you know, Sirona and 3M or whatever, we're just seeing continued growth with those. There's nothing I would say that's asymptotic about it but it's just good strong linear growth going forward and so that's helpful also.
至於第三方的部分,你知道,像 Sirona、3M 或其他,我們只是看到它們持續成長。我不會說有什麼趨近飽和(asymptotic)的狀況,但就是未來持續良好、穩健的線性成長,所以這也很有幫助。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Thanks everyone.
謝謝各位。
Operator
Operator
Your next question comes from Jon Block of Stifel, please go ahead.
下一個問題來自 Stifel 的 Jon Block,請繼續。
Jon Block - Analyst
Jon Block - Analyst
Great guys thanks and good afternoon. I might have two or three and the numbers look really good so I'm actually going to focus on the SDC deal that you announced. The first one Joe I'm just a little confused. You mentioned 1% to 2% cannibalized but when I look at your cases and sort of lean on the Analyst Day, you know, Express seems to be 15% plus so can you sort of [walk] those two numbers or rectify them? Why Express 15% plus, you're cannibalizing 1% or 2%, is that just because of the lack of attachments in the IPR?
太好了,各位謝謝,午安。我可能有兩三個問題,而且數字看起來非常好,所以我其實要聚焦在你們宣布的 SDC 交易。第一個問題,Joe,我有點困惑。你提到 1% 到 2% 的互相侵蝕(cannibalized),但當我看你們的案例數並回想分析師日的內容,你知道,Express 似乎是 15% 以上,所以你能否把這兩個數字(聽不清)串起來或解釋一下?為什麼 Express 是 15% 以上,但你們被侵蝕只有 1% 或 2%?這只是因為 IPR 缺少附件(attachments)嗎?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Hey Jon, it's Joe. You know, when you look at -- there's different protocols on this and so it's not just a number of aligners, it's what's -- so just from an overall standpoint, remember there's no IPR as it's done on these, there's no attachments and obviously on E5 you wouldn't have attachments but E10 you do sometimes. Secondly is SmileDirectClub doesn't move [molars]. They've basically moving (inaudible) and they move them at different velocity and different rates and when you add that all up it really comes down to there's a very small overlap on that piece. Now, your question has to do with our Express line. I think those overlaps are like 4% on E10, 8% on E5, when you run it against our whole portfolio, that's where you get less than 2% for the whole thing. So we have a track pretty well, we know this well, that's why we're confident about the minimal amount of cannibalization we would expect to be going to market.
嗨 Jon,我是 Joe。你知道,當你看——這裡有不同的治療規範(protocols),所以不只是矯正器的數量,還有——從整體角度來看,先記得這些案例不做 IPR,也沒有附件;當然在 E5 你也不會有附件,但 E10 有時候會有。第二點是 SmileDirectClub 不移動[臼齒]。他們基本上是在移動(聽不清),而且移動的速度與幅度也不同。把這些加總起來,最後就會發現那一塊的重疊其實非常小。那你的問題是關於我們的 Express 產品線。我認為這些重疊大概是:E10 約 4%,E5 約 8%;當你把它放到我們整個產品組合來看,整體就會低於 2%。所以我們追蹤得很清楚、也很了解這件事,這就是為什麼我們對預期進入市場後的侵蝕幅度很小有信心。
Jon Block - Analyst
Jon Block - Analyst
Okay, and maybe -- can you give any details on what you're going to ship aligners to, to SDC in terms of the cost that don't pay or the revenue that you'll recognize on those aligners?
好,那也許——你能否提供一些細節,關於你們要出貨矯正器給 SDC 的成本(他們不支付的部分)或你們在那些矯正器上會認列的營收?
David White - CFO
David White - CFO
So we've not disclosed Jon the pricing of those aligners. What we have disclosed is that the pricing is dependent upon volume discounts and as their business ramps they'll earn lower pricing. But when you look at it on an incremental basis, we've priced it basically on a per aligner basis, we believe it's going to be accretive to the company both from a revenue standpoint as well as from an operating margin standpoint.
Jon,我們沒有揭露那些矯正器的定價。我們已揭露的是,定價取決於量的折扣,隨著他們的業務爬坡,他們會取得更低的價格。但如果你從增量的角度來看,我們基本上是以每副矯正器(per aligner)來定價;我們相信這會對公司具增益(accretive),不論是營收面或營業利益率面。
Jon Block - Analyst
Jon Block - Analyst
So I get that and accretive to you guys but is it going to be dilutive to your customers and that's maybe my final question and I've got more and I'll take them offline but that's what I'm having a really hard time here with is Joe you came in and you did such a great job short of walking up to the customer, shaking hands and eliminating the main point of friction with the additional aligner policy and it seems like to me, is this a risk that you just sort of bring back in a main point of friction because you're going to have a subset of docs who believe their Express business and some other cases are now being pointed to an at-home business. Thank you guys.
所以我理解這點,對你們是具增益,但它會不會對你們的客戶造成稀釋(dilutive)?這可能是我最後一個問題——我還有更多,但我會私下再問。我現在很難理解的是,Joe,你上任後做得非常好,幾乎是走到客戶面前握手,把「額外矯正器政策」這個主要摩擦點消除掉;但在我看來,這是否有風險:你們等於又把一個主要摩擦點帶回來,因為會有一部分醫師認為他們的 Express 業務以及其他一些案例,現在被導向居家(at-home)模式。謝謝各位。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Jon, it's a fair question and obviously it was something that we strategically had to wrestle with inside the company as we worked with the SmileDirectClub. But I think you can see that as we work through this, when you look at -- we keep the Invisalign product within SmartTrack, SmartStage, all of the pieces of that, the Invisalign brand name, all of that stays at the doctors office. And also see this is EX30, it's basic dental material that's been out there for years, there's no (inaudible), straight [rail] system, it's going to a group who we feel demographics that are a lot more concerned with convenience and cost and then when we ran those protocols that we just talked about and showed the less than 2% would be an issue for us, from a cannibalization standpoint. I mix that Jon honestly with when you look at what's going on overall in the marketplace right now with direct to consumer, you just saw the thing with Dollar Shave Club and what Unilever had to pay for that company because they were late to that game.
Jon,這是個合理的問題,而且很明顯地,當我們與 SmileDirectClub 合作時,這也是公司內部在策略上必須反覆權衡的議題。但我想你可以看到,當我們把這件事梳理清楚時,如果你看——我們把 Invisalign 產品保留在 SmartTrack、SmartStage,以及所有相關的要素之內;Invisalign 的品牌名稱等等,全部都留在醫師診所端。另外你看,這是 EX30,它是多年來一直存在的基本牙科材料,沒有(聽不清),是直線式[軌道]系統;它面向的是一群我們認為在人口統計上更在意便利性與成本的族群。然後當我們跑完剛才談到的那些治療規範,並顯示對我們而言侵蝕影響會低於 2%。Jon,老實說,我也把這點與目前市場上直面消費者(direct to consumer)的整體趨勢放在一起看:你剛看到 Dollar Shave Club 的案例,以及 Unilever 因為進場太晚而不得不為那家公司支付的價格。
You know, I really felt that for a lot of reasons; both from an offensive standpoint and a new market standpoint, that this would be balanced well with concerns from a customer base. And we'll do our best to ensure our customer base that this is intended that way and we'll work with SDC to continue to target the demographic that they've been targeting and being successful with.
你知道,我確實覺得基於很多原因;無論是從進攻性的角度或是開拓新市場的角度來看,這件事都能在顧客群的疑慮之間取得良好平衡。我們也會盡最大努力向我們的顧客群確保這就是原本的用意,並且會與 SDC 合作,持續鎖定他們一直以來鎖定且已成功觸及的族群。
Jon Block - Analyst
Jon Block - Analyst
All right, thanks for your time guys.
好,謝謝各位撥冗。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yep.
是的。
Operator
Operator
The next question comes from John Kreger of William Blair, please go ahead.
下一個問題來自 William Blair 的 John Kreger,請繼續。
John Kreger - Analyst
John Kreger - Analyst
Hi, thanks very much. I have a capex question. I think at Analyst Day you talked about over the next few years moving both planning and fabrication to Europe and Asia. Can you just remind us the timing of that and if we should assume any sort of a step up in capex to do it? And when you layer the volume of SmileDirect on, will that have to -- will that prompt any sort of retrofitting in Juarez?
嗨,非常感謝。我有一個資本支出(capex)問題。我記得在分析師日你們提到,未來幾年會把規劃與製造都移到歐洲與亞洲。能否提醒一下時程?以及我們是否應該假設為了推動這件事,資本支出會有某種程度的跳升?另外,把 SmileDirect 的量加進來之後,是否會——是否會促使在華雷斯(Juarez)進行任何形式的改裝?
David White - CFO
David White - CFO
So John, you know, we've actually begun some of the activities incidental to expanding our base of international operating activities so as an example, we established in Europe a base where doctors who are submitting physical impressions can send them to a European address to have them scanned versus sending them all of the way to Juarez. So we've implemented that and you've seen -- there's been some capex associated with that and there's been some operating expenses for starting that activity up. We've also begun looking at establishing some [treat] capacity in some of our regions and begun piloting some of that with small numbers of people and experimenting with how we -- how those workflows might work. As it relates to a bigger piece which would be doing a liner fabrication, that's still further out into the future; 2017 plus.
John,你知道,我們其實已經開始了一些與擴大國際營運活動基礎相關的工作。舉例來說,我們在歐洲建立了一個據點,讓提交實體印模的醫師可以寄到歐洲地址進行掃描,而不是一路寄到華雷斯。所以我們已經導入了這個做法,你也看到——這當中有一些相關的資本支出,也有一些啟動該活動的營運費用。我們也開始評估在部分區域建立一些 [treat] 產能,並以少量人數進行試點,測試我們——這些工作流程可能如何運作。至於更大的一塊,也就是進行內襯(liner)製造,那仍然是更久以後的事;2017 年以後。
And so we're beginning to see some of that now and when we look at our gross margins actually for guidance in Q3, there's a little bit of an impact from that. The -- as far as the capex standpoint is concerned, SDC won't really impact that very significantly, their volume is relative to our volumes are still very modest and we wouldn't expect the uptick to be meaningful. As it relates to the rest of our business, probably for the next two years or so, I think, as that infrastructure begins getting placed, you know, geographically, we'd probably see a little bit higher capex then what we'd normally experience and at which point as those operations are established and the brick and mortar is up, we would probably expect capex to return to kind of the nominal rates that we saw historically.
因此我們現在開始看到其中一些影響,而當我們看第三季(Q3)的毛利率指引時,確實會有一點點影響。——就資本支出的角度而言,SDC 不會對此造成非常顯著的影響,他們的量相對於我們的量仍然很小,我們不預期會有有意義的上升。至於我們其餘業務,我想在接下來大約兩年左右,隨著這些基礎設施開始在地理上逐步到位,我們可能會看到資本支出比我們平常的水準略高;等到那些營運據點建立完成、硬體設施到位之後,我們大概會預期資本支出回到過去歷史上看到的那種正常水準。
John Kreger - Analyst
John Kreger - Analyst
Great, thanks and just one more, Joe, stepping back if you think about your opportunity with Clear Aligners, the bigger opportunity would seem to be teens but that tends to have a little bit lower volume growth for you. What do you think you need to do to get teen growth equal to or outpacing your adult case volume?
很好,謝謝。再問一個,Joe,退一步來看,如果你思考你們在透明牙套(Clear Aligners)的機會,更大的機會似乎是在青少年,但那部分對你們而言的量成長往往稍微低一些。你認為需要做什麼,才能讓青少年成長與你們成人病例量成長持平,甚至超越?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yeah, I think it -- at our investors meeting recently in New York I think we laid that out pretty well. When you look at first of all from an R&D standpoint, trying to move from a chronological standpoint back more to the palate expansion and mandibular expansion kind of devices that we announced that we'll have in the marketplace in 2017 is one part of that.
是的,我想——在我們最近於紐約舉行的投資人會議上,我們應該已經把這點說得很清楚。首先從研發(R&D)的角度來看,嘗試在時間序列上往前推進,回到更多像是我們宣布將在 2017 年上市的腭擴張與下顎擴張這類裝置,這是其中一部分。
The second reason (inaudible) how we go to consumers and how we communicate Invisalign capability to the consumer base and honestly a lot of our approach to that marketplace over the years has been primarily about adults and adult demographic and we feel pretty strongly as we move into next year we're going to have to -- really, there's two sides to this teen equation. If you look there's three people involved normally in teens; you have the father or the mother and ten you're going to have the teen and then you also have the doctor. We found that over time you've got to win two out of three and I think often we win the one with the teen, we lose the mom or we lose the doc. And so we're working on both ends hard from an advertising standpoint to make sure that we do better in working with our docs in a sense of our teen capability and expanding it coming forward and then secondly is to get to the mom in a much better way, particularly around compliance. A lot of mothers or fathers have concerns that their teens really will wear these the amount of time that's needed to properly move the teeth. We found out over the years that actually teens are more complaint than adults and so we're very confident.
第二個原因是(聽不清楚)我們如何面向消費者,以及我們如何向消費者群溝通 Invisalign 的能力。老實說,多年來我們對那個市場的很多做法主要聚焦在成人與成人族群;而我們相當確信,進入明年後我們將必須——其實青少年這個方程式有兩個面向。你看,青少年通常會牽涉三個人:父親或母親,然後是青少年本人,還有醫師。我們發現長期來看你必須贏下三者中的兩個;而我認為我們常常贏了青少年,卻輸給媽媽或輸給醫師。因此我們在兩端都很努力:從廣告角度確保我們在與醫師合作、讓他們理解我們的青少年能力並在未來擴大方面做得更好;第二是以更好的方式觸及媽媽,特別是在配戴遵從性(compliance)方面。很多母親或父親擔心他們的孩子是否真的會配戴到足夠的時間,才能正確移動牙齒。我們多年來發現,其實青少年比成人更遵從,因此我們非常有信心。
And frankly the dentition of teens are really helpful in the sense of how loose the dentition is and how fast you can actually move teen teeth. So as we speak, we're working hard in the sense of how we're going to approach teens next year. It is -- it's a great question because it is obviously 75% of the marketplace and it's one that we have not obviously penetrated thoroughly and I think we can make some really good progress in the next year.
而且坦白說,青少年的齒列狀況在某種程度上非常有利,因為齒列較為鬆動,你其實可以更快移動青少年的牙齒。所以就目前而言,我們正努力思考明年要如何切入青少年市場。這——這是個很好的問題,因為那顯然占了市場的 75%,而我們顯然還沒有徹底滲透;我認為我們在明年可以取得非常不錯的進展。
David White - CFO
David White - CFO
Hey John, just to add a little bit of color to Joe's comments there, if you look at our teen growth, our teen growth is still north of 20% year-over-year which we think is really outstanding in a market that's only growing 3% to 4%, you know, that share that we're taking away from wires and brackets. And I think one of the -- when you look at the 20% it may lag our overall growth as a company by maybe a point or two but I think some of that is largely attributable to the fact that our international business is growing faster than what we're growing here in North America and their business is more dominated by adult -- you know, treatment of adults. And so our international business has been growing at those faster rates that it's had somewhat of a dilutive impact on our overall teen growth because our teen is more dominated here in the U.S.
John,我再補充一點 Joe 剛才評論的背景。如果你看我們的青少年成長,我們的青少年成長年增仍在 20% 以上,我們認為在一個只成長 3% 到 4% 的市場中,這表現非常出色——也就是我們從傳統鋼線與托槽那邊拿到的市占。我想其中一點——當你看 20% 時,它可能比我們公司整體成長落後一到兩個百分點,但我認為其中一部分主要是因為我們的國際業務成長速度比北美更快,而他們的業務更以成人——你知道,成人治療為主。因此我們國際業務以更快的速度成長,對我們整體青少年成長率造成了一些稀釋效應,因為我們的青少年業務主要集中在美國。
So we still feel like the teen business is going great and still feel like we've got plenty of opportunities still ahead of us there.
所以我們仍然覺得青少年業務進展得很好,也仍然覺得那裡還有很多機會在前方。
John Kreger - Analyst
John Kreger - Analyst
Very helpful, thanks.
非常有幫助,謝謝。
Operator
Operator
(Operator Instructions). Our next question is from Richard Newitter of Leerink Partners, please go ahead.
(接線員指示)。我們下一個問題來自 Leerink Partners 的 Richard Newitter,請繼續。
Richard Newitter - Analyst
Richard Newitter - Analyst
Hi, thanks for taking the question. Just going back to the SDC, the -- I'm curious if you could characterize for us the type of customer or consumer that kind of -- lead generation aspect of this, type of customer or consumer that's going to SmileDirect and how that compares to who's kind of learning or coming to Clear Aligners through your website? Did you do any research or do you have any information there about the type of consumer that's getting this type of product versus traditionally who goes through the doc locator and traditionally on the Align channel?
嗨,謝謝讓我提問。回到 SDC 這件事——我想了解你們是否能為我們描述一下,這種——這裡的潛在客戶開發(lead generation)面向所對應的客戶或消費者類型:哪些類型的客戶或消費者會去 SmileDirect?以及這與透過你們網站了解或接觸透明牙套(Clear Aligners)的人相比如何?你們是否做過任何研究,或是否有任何資訊,關於購買這類產品的消費者類型,與傳統上透過醫師查找器(doc locator)以及傳統 Align 通路的人有何不同?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
You know, I can say that we don't have exhaustive data on that. I mean, what SmileDirectClub has shared with us, there's -- it tends to be -- The demographic end tends to be heavily weighted toward women versus men which we see in our own demographic. These are people that are really often millennial's, they -- convenience is really important to them. It's -- they have a certain want from a freedom standpoint in the sense of visiting doctors offices. There's obviously a price point here too, it's something simple in the sense of what they want [to move] from a malocclusion standpoint. So it's not -- it's not necessarily a gender difference from what we've done or an age difference, but it's a preference difference in the sense of how people want to engage from what we can see so far.
你知道,我可以說我們沒有非常完整的數據。我的意思是,SmileDirectClub 與我們分享的是——其人口統計特徵似乎——在女性相對於男性的比重上更高,這點我們在自身的人口結構中也看得到。這些人往往是千禧世代,他們——便利性對他們非常重要。——他們在某種程度上希望有更多自由,不想一直跑醫師診所。當然這裡也有價格帶因素,從咬合不正(malocclusion)的角度來看,他們想改善的狀況相對簡單。所以這不一定是性別差異或年齡差異,而是偏好差異:就我們目前所見,人們想要以什麼方式參與與互動。
Richard Newitter - Analyst
Richard Newitter - Analyst
Okay, and then maybe just turning one financial one on gross margin, I think you said that you have some manufacturing startup costs for your APAC kind of initiative there bringing 3M manufacturing closer to that part of the world. That's going to impact the step-down in gross margin in the third quarter. Can you just give us a sense as to whether or not that is kind of finite in nature or should we kind of think of that as kind of a go-forward kind of gross margin rate for future quarters and modeling or how should we think about that? Thanks.
好的。接著再問一個財務問題,關於毛利率:我想你提到你們在亞太(APAC)那邊的計畫有一些製造端的啟動成本,讓 3M 的製造更貼近世界那一端。這會影響第三季毛利率的下滑。你能否讓我們了解一下,這種影響是否屬於一次性、有限的性質?還是我們應該把它視為未來季度在建模時的延續性毛利率水準?我們應該如何看待?謝謝。
David White - CFO
David White - CFO
Yeah, I would say it's probably more of a go-forward rate but let me give you a little bit more color to that because I was answering that question in the context of a capex discussion. When you actually look at the biggest impact on gross margins and the fact that they're declining just slightly quarter-over-quarter the biggest impact is from our scanner business which has a gross margin that is in the low 50s and as that business is growing, more than doubling on a year-over-year basis, it's having a little bit more of a dilutive impact on our overall gross margins.
是的,我會說這可能更像是一個往後適用的費率,但讓我再多補充一些背景,因為我是在資本支出(capex)討論的脈絡下回答那個問題。當你實際去看毛利率最大的影響,以及毛利率為何僅在季度對季度略有下滑時,最大的影響來自我們的掃描器業務;該業務的毛利率在 50% 出頭,而隨著該業務成長、年對年成長超過一倍,它對我們整體毛利率帶來了些許稀釋影響。
But I would say that the guidance that we've given for Q3 is probably the best guidance we could give you on a more going-forward basis as well.
不過我會說,我們對第三季(Q3)所給出的指引,可能也是我們在更往後展望上能提供的最佳指引。
Richard Newitter - Analyst
Richard Newitter - Analyst
Okay, thanks and if I could squeeze one more in. I know you -- I believe you said you had the G6 product launching in the U.S. or you had anticipated that. I was just wondering, any initial feedback there on how that launch is going assuming it's already happened?
好的,謝謝。如果我可以再塞一個問題。我知道你們——我相信你提到 G6 產品會在美國上市,或你們原先是這樣預期的。我只是想問,若上市已經發生了,對於這次上市進展有沒有任何初步回饋?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
We've launched G6 in the U.S. and G6 functions well. I mean, we have good feedback on it but honestly when you look at the demographics again of this, it moves to Asia because extraction cases in Asia are way overboard in a sense of the number of cases they see. So, it's being used in North America, it's been successful, it's growing in that sense but predominantly it's been an APAC product.
我們已在美國推出 G6,而 G6 的運作表現良好。我的意思是,我們收到不錯的回饋,但老實說,當你再看一次這裡的人口結構(demographics),重點會轉向亞洲,因為亞洲的拔牙病例在某種意義上是遠遠超出常態的——就他們看到的病例數而言。所以,它在北美也有使用、也很成功、在那個意義上也在成長,但主要它一直是個亞太(APAC)產品。
Shirley Stacy - VP, Corporate Communications and IR
Shirley Stacy - VP, Corporate Communications and IR
Thanks Rich. Operator, we'll take one last question please.
謝謝你,Rich。接線生,我們請再接最後一個問題。
Operator
Operator
Okay, the last question today comes from Chris Lewis of ROTH Capital Partners, please go ahead.
好的,今天最後一個問題來自 ROTH Capital Partners 的 Chris Lewis,請開始。
Chris Lewis - Analyst
Chris Lewis - Analyst
Hi guys, thanks for squeezing me in. I guess first just on the North American price increase, can you quantify what the increase was and the timing of that and the rest -- just what you've seen since you've implemented that pricing strategy?
嗨,各位,謝謝讓我插個問題。我想先問北美的漲價,你們能量化一下漲幅是多少、何時生效,以及——自從你們實施這個定價策略之後,你們觀察到的情況是什麼?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yeah, the price increase is effective April 1 so we saw just a partial impact of that in the second quarter. The magnitude of the price increase varied dependent upon the product but it primarily applied to our full stage products and varied anywhere from $50.00 to I think $70.00, $80.00.
好的,這次漲價自 4 月 1 日起生效,所以我們在第二季只看到部分影響。漲價幅度依產品而異,但主要適用於我們的全階(full stage)產品,幅度大約從 50 美元到我想是 70 美元、80 美元不等。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay, good. So, it's reasonable to assume that at least in North America, ASP trend up in the third quarter from second quarter?
好的,不錯。所以可以合理假設,至少在北美,第三季的 ASP 走勢會比第二季上升?
David White - CFO
David White - CFO
From a revenue standpoint, yes. There are other factors however though when you go into the third quarter because typically we have more promotion activity going on in the third quarter particularly for teens but holding that aside, you're right.
從營收角度來看,是的。不過進入第三季還有其他因素,因為通常第三季我們會有更多促銷活動,特別是針對青少年;先把那點放一邊,你說得沒錯。
Chris Lewis - Analyst
Chris Lewis - Analyst
Understood. And then just turning to the iTero Element, understand it's going to increase sequentially. You know, are you still working through the backlog there and if so when do you think that will be kind of more on a normalized basis, I guess I'm looking beyond the third quarter and just trying to engage where sales go post 3Q, thanks.
了解。接著談 iTero Element,我理解它會呈現季增。你知道,你們是否仍在消化那邊的積壓訂單(backlog)?如果是的話,你們認為何時會比較回到正常化的水準?我想看的是第三季之後,試著判斷 3Q 之後的銷售走向,謝謝。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
So I think one of the things we've been very fortunate with is that the demand that we saw post the announcement of the product in March of 2015 has continued to almost outpace our ability to deliver and so we've had a very good first half of the year with orders, maintain that backlog in spite of our increased efforts to get ahead of it. We would expect that more nominal rate of backlog would probably be somewhere in half the levels that we have today and we think that would be somewhere in the -- maybe towards the end of the year by the time we'd catch up.
我想我們非常幸運的一點是,自 2015 年 3 月產品發布後所看到的需求,持續到幾乎超過我們的交付能力;因此上半年我們的訂單表現非常好,儘管我們加大努力想要超前消化積壓訂單,但仍維持了那個 backlog。我們預期較為正常的 backlog 水準,大概會是目前的一半左右;我們認為大概會在——也許到年底左右我們才會追上並把它消化到那個程度。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay, great. And then just one more for me. You know, as you think of that bolus of new scanners being placed, it sounds like mostly in the GP channel, you know, when do you think that will really start to translate into utilization and do you think -- is there an immediate pickup, uptick in utilization once a GP receives that scanner or is there a bit of lag effect there? Thanks.
好的,很好。那我再問最後一個。當你們想到那一波新掃描器的裝機,看起來多數是在 GP 通路,你知道,你們認為何時會真正開始轉化為使用量(utilization)?以及你們覺得——GP 一拿到掃描器就會立刻帶來使用量的提升、上升嗎?還是會有一些滯後效應?謝謝。
David White - CFO
David White - CFO
Yeah, we still wrestle with that question, you know, honestly Chris. I think obviously there's an immediate pickup if there's a user today from an Invisalign standpoint, they turn all of their impressions over to iTero and you see an immediate flip but as far as it actually keeps doing more and more cases, we have more and more data to say that's true. We can't quantify exactly right now exactly how true that is and to what degree it occurs.
是的,老實說 Chris,我們仍在苦思這個問題。我想很明顯地,如果今天本來就是 Invisalign 的使用者,會立刻有一個提升:他們會把所有的印模都轉到 iTero,你會看到立即的轉換。但至於它是否會持續做越來越多的病例,我們有越來越多的數據顯示確實如此。不過我們目前還無法精確量化它到底有多真實、以及發生的程度到什麼水平。
Chris Lewis - Analyst
Chris Lewis - Analyst
Okay, thanks for the time.
好的,謝謝撥冗。
Shirley Stacy - VP, Corporate Communications and IR
Shirley Stacy - VP, Corporate Communications and IR
Thank you everyone for -- sorry operator, I'll go ahead and close. Thank you everyone for joining us today, we appreciate your time. If you have any follow-up questions please contact Align Investor Relations.
謝謝各位——抱歉接線生,我來做結語。感謝各位今天加入我們,我們很感謝你們的時間。如有任何後續問題,請聯絡 Align 投資人關係(Investor Relations)。
Operator
Operator
This concludes today's conference, thank you for your participation. You may disconnect your lines at this time.
今天的電話會議到此結束,感謝各位的參與。您現在可以掛斷電話線。